{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:53:38Z","timestamp":1790967218884,"version":"4.1.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Nipple-sparing mastectomy (NSM) has become widely available for breast cancer prophylaxis. There are limited data on its long-term oncologic safety. The objective of this study was to determine the incidence of breast cancer in patients who underwent prophylactic NSM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>All patients undergoing prophylactic NSM at a single institution from 2006 through 2019 were retrospectively reviewed. Patient demographic factors, genetic predispositions, mastectomy specimen pathology, and oncologic occurrences at follow-up were recorded. Descriptive statistics were performed where necessary to classify demographic factors and oncologic characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 871 prophylactic NSMs were performed on 641 patients, with median follow-up of 82.0 months (standard error 1.24). A total of 94.4% of patients (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 605) underwent bilateral NSMs, although only the prophylactic mastectomy was considered. The majority of mastectomy specimens (69.6%) had no identifiable pathology. A total of 38 specimens (4.4%) had cancer identified in mastectomy specimens, with ductal carcinoma in situ being the most common (92.1%;\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 35). Multifocal or multicentric disease was observed in seven cases (18.4%) and lymphovascular invasion was identified in two (5.3%). One patient (0.16%), who was a\n                      <jats:italic toggle=\"yes\">BRCA2<\/jats:italic>\n                      variant carrier, was found to have breast cancer 6.5 years after prophylactic mastectomy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Overall primary oncologic occurrence rates are very low in high-risk patients undergoing prophylactic NSM. In addition to reducing the risk of oncologic occurrence, prophylactic surgery itself may be therapeutic in a small proportion of patients. Continued surveillance for these patients remains important to assess at longer follow-up intervals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CLINICAL QUESTION\/LEVEL OF EVIDENCE:<\/jats:title>\n                    <jats:p>Risk, IV.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/prs.0000000000010481","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T10:11:49Z","timestamp":1680257509000},"page":"37e-43e","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Low Cancer Occurrence Rate following Prophylactic Nipple-Sparing Mastectomy"],"prefix":"10.1097","volume":"153","author":[{"given":"Carter J.","family":"Boyd","sequence":"first","affiliation":[{"name":"Hansj\u00f6rg Wyss Department of Plastic Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sruthi","family":"Ramesh","sequence":"additional","affiliation":[{"name":"Hansj\u00f6rg Wyss Department of Plastic Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Bekisz","sequence":"additional","affiliation":[{"name":"Hansj\u00f6rg Wyss Department of Plastic Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber A.","family":"Guth","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Department of Surgery, New York University Langone Health."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah M.","family":"Axelrod","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Department of Surgery, New York University Langone Health."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Department of Surgery, New York University Langone Health."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Hiotis","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Department of Surgery, New York University Langone Health."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freya R.","family":"Schnabel","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Department of Surgery, New York University Langone Health."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nolan S.","family":"Karp","sequence":"additional","affiliation":[{"name":"Hansj\u00f6rg Wyss Department of Plastic Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihye","family":"Choi","sequence":"additional","affiliation":[{"name":"Hansj\u00f6rg Wyss Department of Plastic Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,3,30]]},"reference":[{"key":"R1-20261002","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10549-016-3975-9","article-title":"Trends and variation in the use of nipple-sparing mastectomy for breast cancer in the United States.","volume":"160","author":"Sisco","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"R2-20261002","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1245\/s10434-019-07948-x","article-title":"Increase in utilization of nipple-sparing mastectomy for breast cancer: indications, complications, and oncologic outcomes.","volume":"27","author":"Valero","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"R3-20261002","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1097\/PRS.0000000000005600","article-title":"Oncologic trends, outcomes, and risk factors for locoregional recurrence: an analysis of tumor-to-nipple distance and critical factors in therapeutic nipple-sparing mastectomy.","volume":"143","author":"Frey","year":"2019","journal-title":"Plast Reconstr Surg"},{"key":"R4-20261002","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/SLA.0b013e3181d35bf8","article-title":"Comparison of skin-sparing mastectomy versus non-skin-sparing mastectomy for breast cancer: a meta-analysis of observational studies.","volume":"251","author":"Lanitis","year":"2010","journal-title":"Ann Surg"},{"key":"R5-20261002","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.breast.2015.08.001","article-title":"Neoadjuvant chemotherapy is not a contraindication for nipple sparing mastectomy.","volume":"24","author":"Santoro","year":"2015","journal-title":"Breast"},{"key":"R6-20261002","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1245\/s10434-014-3883-3","article-title":"Nipple-sparing mastectomy in BRCA1\/2 mutation carriers: an interim analysis and review of the literature.","volume":"22","author":"Yao","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"R7-20261002","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/bjs.9884","article-title":"Nipplesparing mastectomy in patients with BRCA1\/2 mutations and variants of uncertain significance.","volume":"102","author":"Wood","year":"2015","journal-title":"Br J Surg"},{"key":"R8-20261002","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/PAS.0000000000000180","article-title":"Prophylactic nipple-sparing mastectomy leaves more terminal duct lobular units in situ as compared with skin-sparing mastectomy.","volume":"38","author":"van Verschuer","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"R9-20261002","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.","volume":"302","author":"King","year":"2003","journal-title":"Science"},{"key":"R10-20261002","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJM199705153362001","article-title":"The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.","volume":"336","author":"Struewing","year":"1997","journal-title":"N Engl J Med"},{"key":"R12-20261002","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.1245\/s10434-021-10445-9","article-title":"How protective are nipple-sparing prophylactic mastectomies in BRCA1 and BRCA2 mutation carriers?","volume":"28","author":"Garstka","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"R13-20261002","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1097\/PRS.0b013e3181ef8bce","article-title":"Nipple-sparing mastectomy with immediate implant reconstruction: cosmetic outcomes and technical refinements.","volume":"126","author":"Salgarello","year":"2010","journal-title":"Plast Reconstr Surg"},{"key":"R14-20261002","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJM199901143400201","article-title":"Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer.","volume":"340","author":"Hartmann","year":"1999","journal-title":"N Engl J Med"},{"key":"R15-20261002","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1056\/NEJM200107193450301","article-title":"Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.","volume":"345","author":"Meijers-Heijboer","year":"2001","journal-title":"N Engl J Med"},{"key":"R16-20261002","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/PAS.0000000000000180","article-title":"Prophylactic nipple-sparing mastectomy leaves more terminal duct lobular units in situ as compared with skin-sparing mastectomy.","volume":"38","author":"van Verschuer","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"R17-20261002","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.suronc.2019.04.009","article-title":"Residual glandular tissue (RGT) in BRCA1\/2 germline mutation carriers with unilateral and bilateral prophylactic mastectomies.","volume":"29","author":"Grinstein","year":"2019","journal-title":"Surg Oncol"},{"key":"R18-20261002","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/00000637-198312000-00016","article-title":"Subcutaneous mastectomy: current state of the art.","volume":"11","author":"Woods","year":"1983","journal-title":"Ann Plast Surg"},{"key":"R19-20261002","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.ejso.2018.05.006","article-title":"Nipple-areolar complex ischemia and necrosis in nipple-sparing mastectomy.","volume":"44","author":"Ahn","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"R20-20261002","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/bjs.9884","article-title":"Nipple-sparing mastectomy in patients with BRCA1\/2 mutations and variants of uncertain significance.","volume":"102","author":"Manning","year":"2015","journal-title":"J Br Surg"},{"key":"R21-20261002","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1097\/PRS.0b013e31822b6456","article-title":"Nipple-sparing mastectomy for prophylactic and therapeutic indications.","volume":"128","author":"Spear","year":"2011","journal-title":"Plast Reconstr Surg"},{"key":"R22-20261002","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jamasurg.2017.3422","article-title":"Oncologic safety of prophylactic nipple-sparing mastectomy in a population with BRCA mutations: a multi-institutional study.","volume":"153","author":"Jakub","year":"2018","journal-title":"JAMA Surg"},{"key":"R23-20261002","doi-asserted-by":"crossref","first-page":"247","DOI":"10.21037\/gs.2017.09.10","article-title":"Evidence based outcomes of the American Society of Breast Surgeons Nipple-Sparing Mastectomy Registry.","volume":"7","author":"Mitchell","year":"2018","journal-title":"Gland Surg"},{"key":"R24-20261002","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/j.anplas.2017.09.005","article-title":"Oncological safety of nipple-sparing prophylactic mastectomy: a review of the literature on 3716 cases.","volume":"63","author":"Muller","year":"2018","journal-title":"Ann Chir Plast Esthet"},{"key":"R25-20261002","doi-asserted-by":"crossref","first-page":"e5087","DOI":"10.1097\/GOX.0000000000005087","article-title":"No cancer occurrences in 10-year follow-up after prophylactic nipple-sparing mastectomy.","volume":"11","author":"Boyd","year":"2023","journal-title":"Plast Reconstr Surg Glob Open"}],"container-title":["Plastic &amp; Reconstructive Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PRS.0000000000010481","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:01:04Z","timestamp":1790964064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/PRS.0000000000010481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,30]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/prs.0000000000010481","relation":{},"ISSN":["0032-1052","1529-4242"],"issn-type":[{"value":"0032-1052","type":"print"},{"value":"1529-4242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,30]]}}}